Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 8.42 USD 1.08% Market Closed
Market Cap: 56.3m USD

Intrinsic Value

ATRA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ATRA stock under the Base Case scenario is 19.48 USD. Compared to the current market price of 8.42 USD, Atara Biotherapeutics Inc is Undervalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ATRA Intrinsic Value
19.48 USD
Undervaluation 57%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Atara Biotherapeutics Inc

Valuation History Unavailable

Historical valuation for ATRA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ATRA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Atara Biotherapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Atara Biotherapeutics Inc

Current Assets 27.2m
Cash & Short-Term Investments 13.8m
Receivables 8.9m
Other Current Assets 4.5m
Non-Current Assets 34.9m
PP&E 32m
Other Non-Current Assets 2.8m
Efficiency

Free Cash Flow Analysis
Atara Biotherapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Atara Biotherapeutics Inc

Revenue
199.7m USD
Cost of Revenue
-39.5m USD
Gross Profit
160.3m USD
Operating Expenses
-159.4m USD
Operating Income
880k USD
Other Expenses
-16.5m USD
Net Income
-15.6m USD
Fundamental Scores

ATRA Profitability Score
Profitability Due Diligence

Atara Biotherapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
34/100
Profitability
Score

Atara Biotherapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

ATRA Solvency Score
Solvency Due Diligence

Atara Biotherapeutics Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
27/100
Solvency
Score

Atara Biotherapeutics Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 15.64 USD with a low forecast of 11.11 USD and a high forecast of 18.9 USD.

Lowest
Price Target
11.11 USD
32% Upside
Average
Price Target
15.64 USD
86% Upside
Highest
Price Target
18.9 USD
124% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Atara Biotherapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ATRA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ATRA Insider Trading
Buy and sell transactions by insiders

ATRA News

Other Videos
What is the Intrinsic Value of one ATRA stock?

The intrinsic value of one ATRA stock under the Base Case scenario is 19.48 USD.

Is ATRA stock undervalued or overvalued?

Compared to the current market price of 8.42 USD, Atara Biotherapeutics Inc is Undervalued by 57%.

Back to Top